Literature DB >> 12351400

Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis.

E Marion Schneider1, Ingrid Lorenz, Michaela Müller-Rosenberger, Gerald Steinbach, Martina Kron, Gritta E Janka-Schaub.   

Abstract

In 65 patients with hemophagocytic lymphohistiocytosis (HLH), we found an as yet undescribed heterogeneity of defects in cellular cytotoxicity when assay conditions were modified by the incubation time, the presence of mitogen, or interleukin-2 (IL-2). The standard 4-hour natural killer (NK) test against K562 targets was negative in all patients. In patients deficient in type 1 (n = 21), type 2 (n = 5), and type 4 (n = 8) HLH, negative NK function could be reconstituted by mitogen, by IL-2, or by prolongation of the incubation time (16 hours), respectively. Most patients (n = 31) displayed the type 3 defect, defined by a lack of any cellular cytotoxicity independent of assay variations. The characteristic hypercytokinemia also concerned counterregulatory cytokines, such as proinflammatory interferon-gamma (IFN-gamma), simultaneously elevated with suppressive IL-10 in 38% of types 1-, 2-, and 4-deficient patients and in 71% of type 3-deficient patients. Elevated IFN-gamma alone correlated with high liver enzymes, but sCD95-ligand and sCD25 did not-though these markers were expected to indicate the extent of histiocytic organ infiltration. Outcome analysis revealed more deaths in patients with type 3 deficiency (P =.017). Molecular defects were associated with homozygously mutated perforin only in 4 patients, but other type 3 patients expressed normal transcripts of effector molecules for target-cell apoptosis, including perforin and granzyme family members, as demonstrated by RNase protection analysis. Thus, target-cell recognition or differentiation defects are likely to explain this severe phenotype in HLH. Hyperactive phagocytes combined with NK defects may imply defects on the level of the antigen-presenting cell.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12351400     DOI: 10.1182/blood-2001-12-0260

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

Review 1.  New frontiers in primary immunodeficiency disorders: immunology and beyond….

Authors:  Eleonora Gambineri
Journal:  Cell Mol Life Sci       Date:  2011-10-19       Impact factor: 9.261

2.  Preparation of cryofixed cells for improved 3D ultrastructure with scanning transmission electron tomography.

Authors:  Katharina Höhn; Michaela Sailer; Li Wang; Myriam Lorenz; Marion E Schneider; Paul Walther
Journal:  Histochem Cell Biol       Date:  2010-11-27       Impact factor: 4.304

3.  Evaluating the optimal serum ferritin level to identify hemophagocytic lymphohistiocytosis in the critical care setting.

Authors:  Hayder Saeed; Ryan R Woods; Joshua Lester; Roger Herzig; Zartash Gul; Gregory Monohan
Journal:  Int J Hematol       Date:  2015-05-22       Impact factor: 2.490

4.  Application of an improved flow cytometry-based NK cell activity assay in adult hemophagocytic lymphohistiocytosis.

Authors:  Jia Zhang; Yini Wang; Lin Wu; Jingshi Wang; Ran Tang; Shuo Li; Jianhang Chen; Zhuo Gao; Ruijun Pei; Zhao Wang
Journal:  Int J Hematol       Date:  2017-02-09       Impact factor: 2.490

5.  Adult-Onset Still's Disease and Macrophage-Activating Syndrome Progressing to Lymphoma: A Clinical Pathology Conference Held by the Division of Rheumatology at Hospital for Special Surgery.

Authors:  Bella Mehta; Shanthini Kasturi; Julie Teruya-Feldstein; Steven Horwitz; Anne R Bass; Doruk Erkan
Journal:  HSS J       Date:  2018-03-26

6.  Familial Hemophagocytic Lymphohistiocytosis due to Mutation of UNC13D Gene.

Authors:  Prabhas Prasun Giri; Nirmoy Biswas; Swati Chakravarty
Journal:  Indian J Hematol Blood Transfus       Date:  2015-01-20       Impact factor: 0.900

7.  Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3.

Authors:  Emma M Haapaniemi; Meri Kaustio; Hanna L M Rajala; Arjan J van Adrichem; Leena Kainulainen; Virpi Glumoff; Rainer Doffinger; Heikki Kuusanmäki; Tarja Heiskanen-Kosma; Luca Trotta; Samuel Chiang; Petri Kulmala; Samuli Eldfors; Riku Katainen; Sanna Siitonen; Marja-Liisa Karjalainen-Lindsberg; Panu E Kovanen; Timo Otonkoski; Kimmo Porkka; Kaarina Heiskanen; Arno Hänninen; Yenan T Bryceson; Raija Uusitalo-Seppälä; Janna Saarela; Mikko Seppänen; Satu Mustjoki; Juha Kere
Journal:  Blood       Date:  2014-10-27       Impact factor: 22.113

8.  Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies.

Authors:  E Rudd; K Göransdotter Ericson; C Zheng; Z Uysal; A Ozkan; A Gürgey; B Fadeel; M Nordenskjöld; J-I Henter
Journal:  J Med Genet       Date:  2006-04       Impact factor: 6.318

9.  Pediatric hemophagocytic syndromes: a diagnostic and therapeutic challenge.

Authors:  Nada Jabado; Christine McCusker; Genevieve de Saint Basile
Journal:  Allergy Asthma Clin Immunol       Date:  2005-12-15       Impact factor: 3.406

10.  Beta-blocker therapy and hemophagocytic lymphohistiocytosis: a case report.

Authors:  C Müller; L B Mänhardt; C Willaschek; E M Schneider; E A Stuth; R Buchhorn
Journal:  Cardiol Res Pract       Date:  2010-06-20       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.